Details for: PLK3
Gene ID: 1263
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: PLK3
Ensembl ID: ENSG00000173846
Description: polo like kinase 3
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 14.9rCSI 17.23%PRS 65.95
-
CSI 12.73rCSI 12.97%PRS 85.19
-
CSI 11.18rCSI 36.25%PRS 72.87
-
CSI 8.62rCSI 11.75%PRS 92.72
-
CSI 6.58rCSI 14.48%PRS 78.47
-
CSI 5.35rCSI 5.54%PRS 79.2
-
CSI 5.11rCSI 9.22%PRS 90.96
-
CSI 5.02rCSI 6.24%PRS 75.74
-
CSI 4.91rCSI 4.54%PRS 89.88
-
CSI 4.85rCSI 6.85%PRS 75.25
-
CSI 4.73rCSI 5.86%PRS 71.81
-
CSI 4.66rCSI 3.86%PRS 74.77
-
CSI 4.11rCSI 2.73%PRS 77.32
-
CSI 3.97rCSI 14.38%PRS 90.53
-
CSI 3.92rCSI 2.98%PRS 87.14
-
CSI 3.87rCSI 3.01%PRS 89.55
-
CSI 3.87rCSI 3.1%PRS 89.78
-
CSI 3.65rCSI 6.91%PRS 94.71
-
CSI 3.53rCSI 5.63%PRS 78.09
-
CSI 3.29rCSI 2.29%PRS 85.85
-
CSI 3.17rCSI 3.99%PRS 84.57
-
CSI 3.14rCSI 8.13%PRS 92.32
-
CSI 2.83rCSI 4.41%PRS 92.71
-
CSI 2.83rCSI 2.03%PRS 87.52
-
CSI 2.79rCSI 2.17%PRS 77.66
-
CSI 2.79rCSI 2.92%PRS 89.51
-
CSI 2.78rCSI 6.25%PRS 87.86
-
CSI 2.73rCSI 2.4%PRS 79.53
-
CSI 2.7rCSI 2.69%PRS 68.01
-
CSI 2.62rCSI 2.17%PRS 76.9
-
CSI 2.58rCSI 1.95%PRS 87.05
-
CSI 2.57rCSI 1.52%PRS 90.03
-
CSI 2.48rCSI 1.86%PRS 87.69
-
CSI 2.38rCSI 3.3%PRS 72.58
-
CSI 2.31rCSI 2.71%PRS 88.68
-
CSI 2.3rCSI 1.78%PRS 76.67
-
CSI 2.28rCSI 2.85%PRS 84.08
-
CSI 2.27rCSI 2.23%PRS 88.45
-
CSI 2.23rCSI 4.42%PRS 81.79
-
CSI 2.2rCSI 1.75%PRS 91.95
-
CSI 2.17rCSI 2.97%PRS 79.29
-
CSI 2.15rCSI 1.61%PRS 80.45
-
CSI 2.12rCSI 1.88%PRS 72.31
-
CSI 2.11rCSI 1.72%PRS 74.15
-
CSI 2.11rCSI 1.96%PRS 75.02
-
CSI 2.09rCSI 2.74%PRS 86.11
-
CSI 1.98rCSI 2.07%PRS 71.51
-
CSI 1.95rCSI 2.82%PRS 81.49
-
CSI 1.95rCSI 1.31%PRS 87.58
-
CSI 1.93rCSI 3.64%PRS 87.1
-
CSI 1.92rCSI 2.93%PRS 82.63
-
CSI 1.89rCSI 2.72%PRS 82.65
-
CSI 1.82rCSI 4.34%PRS 79.52
-
CSI 1.81rCSI 3.75%PRS 71.35
-
CSI 1.8rCSI 1.58%PRS 62.83
-
CSI 1.8rCSI 1.5%PRS 77.59
-
CSI 1.77rCSI 1.71%PRS 66.65
-
CSI 1.76rCSI 3.36%PRS 85.57
-
CSI 1.73rCSI 2.21%PRS 70.63
-
CSI 1.7rCSI 1.56%PRS 82.86
-
CSI 1.67rCSI 1.83%PRS 76.89
-
CSI 1.67rCSI 2.56%PRS 83.47
-
CSI 1.66rCSI 2.54%PRS 74.65
-
CSI 1.64rCSI 1.49%PRS 72
-
CSI 1.64rCSI 1.51%PRS 75.97
-
CSI 1.61rCSI 1.55%PRS 73.71
-
CSI 1.6rCSI 3.4%PRS 81.99
-
CSI 1.53rCSI 2.37%PRS 73.36
-
CSI 1.53rCSI 2.33%PRS 87.08
-
CSI 1.52rCSI 3.27%PRS 82.61
-
CSI 1.47rCSI 2.99%PRS 52.4
-
CSI 1.45rCSI 1.75%PRS 82.65
-
CSI 1.42rCSI 1.9%PRS 73.41
-
CSI 1.4rCSI 2.22%PRS 76.18
-
CSI 1.39rCSI 3.99%PRS 91.56
-
CSI 1.39rCSI 3.65%PRS 88.03
-
CSI 1.38rCSI 1.77%PRS 78.1
-
CSI 1.37rCSI 1.4%PRS 84.23
-
CSI 1.37rCSI 2.63%PRS 93.22
-
CSI 1.36rCSI 1.18%PRS 78.87
-
CSI 1.35rCSI 2.03%PRS 79.58
-
CSI 1.32rCSI 3.81%PRS 82.57
-
CSI 1.29rCSI 2.87%PRS 82.03
-
CSI 1.23rCSI 23.74%PRS 84.58
-
CSI 1.22rCSI 1.46%PRS 90.22
-
CSI 1.22rCSI 3.5%PRS 82.89
-
CSI 1.19rCSI 2.72%PRS 68.89
-
CSI 1.19rCSI 3.14%PRS 82.13
-
CSI 1.19rCSI 3.4%PRS 82.86
-
CSI 1.12rCSI 1.92%PRS 88.69
-
CSI 1.12rCSI 2.65%PRS 75.92
-
CSI 1.1rCSI 2.33%PRS 87.22
-
CSI 1.09rCSI 3.83%PRS 83.74
-
CSI 1.04rCSI 1.79%PRS 81.61
-
CSI 1rCSI 1.89%PRS 83.41
-
CSI 0.97rCSI 1.17%PRS 56.66
-
CSI 0.96rCSI 4.34%PRS 84.06
-
CSI 0.96rCSI 2.58%PRS 80.15
-
CSI 0.75rCSI 3.48%PRS 88.22
-
CSI 0.69rCSI 4.15%PRS 87.71
-
CSI 0.3rCSI 3.2%PRS 86.0%
-
CSI 0.4rCSI 1.4%PRS 80.1%
-
CSI 0.5rCSI 2.0%PRS 83.3%
-
CSI 0.6rCSI 4.0%PRS 83.1%
-
CSI 0.6rCSI 2.5%PRS 82.0%
-
CSI 0.7rCSI 3.8%PRS 80.1%
-
CSI 0.7rCSI 4.2%PRS 87.7%
-
CSI 0.8rCSI 3.5%PRS 88.2%
-
CSI 1.0rCSI 2.6%PRS 80.2%
-
CSI 1.0rCSI 4.3%PRS 84.1%
-
CSI 1.0rCSI 1.2%PRS 56.7%
-
CSI 1.0rCSI 1.9%PRS 83.4%
-
CSI 1.0rCSI 1.8%PRS 81.6%
-
CSI 1.1rCSI 3.8%PRS 83.7%
-
CSI 1.1rCSI 2.3%PRS 87.2%
-
CSI 1.1rCSI 2.7%PRS 75.9%
-
CSI 1.1rCSI 1.9%PRS 88.7%
-
CSI 1.2rCSI 3.4%PRS 82.9%
-
CSI 1.2rCSI 3.1%PRS 82.1%
-
CSI 1.2rCSI 2.7%PRS 68.9%
-
CSI 1.2rCSI 3.5%PRS 82.9%
-
CSI 1.2rCSI 1.5%PRS 90.2%
-
CSI 1.2rCSI 23.7%PRS 84.6%
-
CSI 1.3rCSI 2.9%PRS 82.0%
-
CSI 1.3rCSI 3.8%PRS 82.6%
-
CSI 1.4rCSI 2.0%PRS 79.6%
-
CSI 1.4rCSI 1.2%PRS 78.9%
-
CSI 1.4rCSI 2.6%PRS 93.2%
-
CSI 1.4rCSI 1.4%PRS 84.2%
-
CSI 1.4rCSI 1.8%PRS 78.1%
-
CSI 1.4rCSI 3.7%PRS 88.0%
-
CSI 1.4rCSI 4.0%PRS 91.6%
-
CSI 1.4rCSI 2.2%PRS 76.2%
-
CSI 1.4rCSI 1.9%PRS 73.4%
-
CSI 1.5rCSI 1.8%PRS 82.7%
-
CSI 1.5rCSI 3.0%PRS 52.4%
-
CSI 1.5rCSI 3.3%PRS 82.6%
-
CSI 1.5rCSI 2.3%PRS 87.1%
-
CSI 1.5rCSI 2.4%PRS 73.4%
-
CSI 1.6rCSI 3.4%PRS 82.0%
-
CSI 1.6rCSI 1.6%PRS 73.7%
-
CSI 1.6rCSI 1.5%PRS 76.0%
-
CSI 1.6rCSI 1.5%PRS 72.0%
-
CSI 1.7rCSI 2.5%PRS 74.7%
-
CSI 1.7rCSI 2.6%PRS 83.5%
-
CSI 1.7rCSI 1.8%PRS 76.9%
-
CSI 1.7rCSI 1.6%PRS 82.9%
-
CSI 1.7rCSI 2.2%PRS 70.6%
-
CSI 1.8rCSI 3.4%PRS 85.6%
-
CSI 1.8rCSI 1.7%PRS 66.7%
-
CSI 1.8rCSI 1.5%PRS 77.6%
-
CSI 1.8rCSI 1.6%PRS 62.8%
-
CSI 1.8rCSI 3.8%PRS 71.4%
-
CSI 1.8rCSI 4.3%PRS 79.5%
-
CSI 1.9rCSI 2.7%PRS 82.7%
-
CSI 1.9rCSI 2.9%PRS 82.6%
-
CSI 1.9rCSI 3.6%PRS 87.1%
-
CSI 2.0rCSI 1.3%PRS 87.6%
-
CSI 2.0rCSI 2.8%PRS 81.5%
-
CSI 2.0rCSI 2.1%PRS 71.5%
-
CSI 2.1rCSI 2.7%PRS 86.1%
-
CSI 2.1rCSI 2.0%PRS 75.0%
-
CSI 2.1rCSI 1.7%PRS 74.2%
-
CSI 2.1rCSI 1.9%PRS 72.3%
-
CSI 2.2rCSI 1.6%PRS 80.5%
-
CSI 2.2rCSI 3.0%PRS 79.3%
-
CSI 2.2rCSI 1.8%PRS 92.0%
-
CSI 2.2rCSI 4.4%PRS 81.8%
-
CSI 2.3rCSI 2.2%PRS 88.5%
-
CSI 2.3rCSI 2.9%PRS 84.1%
-
CSI 2.3rCSI 1.8%PRS 76.7%
-
CSI 2.3rCSI 2.7%PRS 88.7%
-
CSI 2.4rCSI 3.3%PRS 72.6%
-
CSI 2.5rCSI 1.9%PRS 87.7%
-
CSI 2.6rCSI 1.5%PRS 90.0%
-
CSI 2.6rCSI 2.0%PRS 87.1%
-
CSI 2.6rCSI 2.2%PRS 76.9%
-
CSI 2.7rCSI 2.7%PRS 68.0%
-
CSI 2.7rCSI 2.4%PRS 79.5%
-
CSI 2.8rCSI 6.3%PRS 87.9%
-
CSI 2.8rCSI 2.9%PRS 89.5%
-
CSI 2.8rCSI 2.2%PRS 77.7%
-
CSI 2.8rCSI 2.0%PRS 87.5%
-
CSI 2.8rCSI 4.4%PRS 92.7%
-
CSI 3.1rCSI 8.1%PRS 92.3%
-
CSI 3.2rCSI 4.0%PRS 84.6%
-
CSI 3.3rCSI 2.3%PRS 85.9%
-
CSI 3.5rCSI 5.6%PRS 78.1%
-
CSI 3.7rCSI 6.9%PRS 94.7%
-
CSI 3.9rCSI 3.1%PRS 89.8%
-
CSI 3.9rCSI 3.0%PRS 89.6%
-
CSI 3.9rCSI 3.0%PRS 87.1%
-
CSI 4.0rCSI 14.4%PRS 90.5%
-
CSI 4.1rCSI 2.7%PRS 77.3%
-
CSI 4.7rCSI 3.9%PRS 74.8%
-
CSI 4.7rCSI 5.9%PRS 71.8%
-
CSI 4.9rCSI 6.9%PRS 75.3%
-
CSI 4.9rCSI 4.5%PRS 89.9%
-
CSI 5.0rCSI 6.2%PRS 75.7%
-
CSI 5.1rCSI 9.2%PRS 91.0%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 496121503
Symbol: PLK3_HUMAN
Name: Serine/threonine-protein kinase PLK3
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 11039900
Title: Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages.
PubMed ID: 11039900
PubMed ID: 16710414
Title: The DNA sequence and biological annotation of human chromosome 1.
PubMed ID: 16710414
DOI: 10.1038/nature04727
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 8702627
Title: Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas.
PubMed ID: 8702627
PubMed ID: 11746980
Title: Intron/exon organization and polymorphisms of the PLK3/PRK gene in human lung carcinoma cell lines.
PubMed ID: 11746980
DOI: 10.1002/gcc.1204
PubMed ID: 12242661
Title: Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways.
PubMed ID: 12242661
PubMed ID: 9353331
Title: Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions.
PubMed ID: 9353331
PubMed ID: 10557092
Title: The physical association and phosphorylation of Cdc25C protein phosphatase by Prk.
PubMed ID: 10557092
PubMed ID: 11156373
Title: Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3.
PubMed ID: 11156373
PubMed ID: 11447225
Title: Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3.
PubMed ID: 11447225
PubMed ID: 11551930
Title: Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway.
PubMed ID: 11551930
PubMed ID: 11971976
Title: Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity.
PubMed ID: 11971976
PubMed ID: 14980500
Title: Polo-like kinase 3 is Golgi localized and involved in regulating Golgi fragmentation during the cell cycle.
PubMed ID: 14980500
PubMed ID: 14968113
Title: Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation.
PubMed ID: 14968113
PubMed ID: 15021912
Title: MEK1-induced Golgi dynamics during cell cycle progression is partly mediated by Polo-like kinase-3.
PubMed ID: 15021912
PubMed ID: 16478733
Title: Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis.
PubMed ID: 16478733
PubMed ID: 16481012
Title: Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage.
PubMed ID: 16481012
PubMed ID: 17804415
Title: Stress-induced c-Jun activation mediated by Polo-like kinase 3 in corneal epithelial cells.
PubMed ID: 17804415
PubMed ID: 17264206
Title: Polo-like kinase 3 is required for entry into S phase.
PubMed ID: 17264206
PubMed ID: 18062778
Title: Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1.
PubMed ID: 18062778
DOI: 10.1042/bj20071394
PubMed ID: 18650425
Title: Activation of Polo-like kinase 3 by hypoxic stresses.
PubMed ID: 18650425
PubMed ID: 19490146
Title: Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation.
PubMed ID: 19490146
PubMed ID: 19103756
Title: Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces Golgi fragmentation.
PubMed ID: 19103756
DOI: 10.1128/mcb.01341-08
PubMed ID: 20889502
Title: Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha.
PubMed ID: 20889502
PubMed ID: 20940307
Title: Regulation of PTEN stability and activity by Plk3.
PubMed ID: 20940307
PubMed ID: 20951827
Title: Calcium- and integrin-binding protein 1 regulates microtubule organization and centrosome segregation through polo like kinase 3 during cell cycle progression.
PubMed ID: 20951827
PubMed ID: 20473878
Title: Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.
PubMed ID: 20473878
DOI: 10.1002/ijc.25388
PubMed ID: 21098032
Title: Hyperosmotic stress-induced ATF-2 activation through Polo-like kinase 3 in human corneal epithelial cells.
PubMed ID: 21098032
PubMed ID: 21840391
Title: Bcl-xL phosphorylation at Ser49 by polo kinase 3 during cell cycle progression and checkpoints.
PubMed ID: 21840391
PubMed ID: 21376736
Title: Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA damage but is not sufficient to produce tumors.
PubMed ID: 21376736
PubMed ID: 21264284
Title: Calcium- and integrin-binding protein 1 regulates endomitosis and its interaction with Polo-like kinase 3 is enhanced in endomitotic Dami cells.
PubMed ID: 21264284
PubMed ID: 20671765
Title: Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
PubMed ID: 20671765
DOI: 10.1038/nrd3184
Sequence Information:
- Length: 646
- Mass: 71629
- Checksum: 324CA3E9DE482514
- Sequence:
MEPAAGFLSP RPFQRAAAAP APPAGPGPPP SALRGPELEM LAGLPTSDPG RLITDPRSGR TYLKGRLLGK GGFARCYEAT DTETGSAYAV KVIPQSRVAK PHQREKILNE IELHRDLQHR HIVRFSHHFE DADNIYIFLE LCSRKSLAHI WKARHTLLEP EVRYYLRQIL SGLKYLHQRG ILHRDLKLGN FFITENMELK VGDFGLAARL EPPEQRKKTI CGTPNYVAPE VLLRQGHGPE ADVWSLGCVM YTLLCGSPPF ETADLKETYR CIKQVHYTLP ASLSLPARQL LAAILRASPR DRPSIDQILR HDFFTKGYTP DRLPISSCVT VPDLTPPNPA RSLFAKVTKS LFGRKKKSKN HAQERDEVSG LVSGLMRTSV GHQDARPEAP AASGPAPVSL VETAPEDSSP RGTLASSGDG FEEGLTVATV VESALCALRN CIAFMPPAEQ NPAPLAQPEP LVWVSKWVDY SNKFGFGYQL SSRRVAVLFN DGTHMALSAN RKTVHYNPTS TKHFSFSVGA VPRALQPQLG ILRYFASYME QHLMKGGDLP SVEEVEVPAP PLLLQWVKTD QALLMLFSDG TVQVNFYGDH TKLILSGWEP LLVTFVARNR SACTYLASHL RQLGCSPDLR QRLRYALRLL RDRSPA